Viking Therapeutics,Inc. v. Ascletis Bioscience Co., Ltd.

• Court: District Court, S.D. California
• Decided: April 8, 2024
• Docket: 3:22-cv-02062
• Status: Unknown

Opinion

1 2 3 4 5 6 7 UNITED STATES DISTRICT COURT 8 SOUTHERN DISTRICT OF CALIFORNIA 9 10 VIKING THERAPEUTICS, INC., Case No.: 3:22-cv-02062-H-VET

11 Plaintiff, ORDER GRANTING, IN PART, AND 12 v. DENYING, IN PART, RIMON, P.C.’S MOTION TO WITHDRAW AS 13 ASCLETIS BIOSCIENCE CO., LTD.; COUNSEL GANNEX PHARMA CO., LTD.; 14 ASCLETIS PHARMACEUTICALS CO., [Doc. No. 36.] 15 LTD.; ASCLETIS PHARMA INC.; and JINZI JASON WU, 16 Defendants. 17 18 On April 3, 2023, the Court stayed the present action pursuant to 28 U.S.C. § 1659(a) 19 pending the final decision in ITC Investigation No. 337-TA-1352. (Doc. No. 31.) On 20 February 5, 2024, Michael F. Heafey and Matthew H. Poppe of Rimon, P.C. (“Rimon”), 21 counsel currently representing Defendants Ascletis Bioscience Co., Ltd., Gannex Pharma 22 Co., Ltd., Ascletis Pharmaceuticals Co. Ltd., Ascletis Pharma Inc., and Jinzi Jason Wu 23 (collectively, “Defendants”), filed a motion to withdraw as counsel in this action for 24 Defendants. (Doc. No. 36.) On February 23, 2024, Plaintiff Viking Therapeutics, Inc. 25 (“Plaintiff”) filed a response in opposition to Rimon’s motion to withdraw as counsel. 26 (Doc. No. 37.) On March 4, 2024, Rimon filed a reply. (Doc. No. 38.) On 27 March 12, 2024, the Court, pursuant to its discretion under Local Rule 7.1(d)(1), submitted 28 the motion on the parties’ papers. (Doc. No. 40.) The Court further directed Rimon to 1 provide contact information for Defendant Wu. (Id.) On March 19, 2024, Rimon filed 2 supplemental briefing regarding Defendant Wu’s contact information. (Doc. No. 41.) On 3 March 20, 2024, Plaintiff filed a response to Rimon’s supplemental briefing. (Doc. 4 No. 42.) On March 21, 2024, Rimon filed additional supplemental briefing regarding 5 Defendant Wu’s contact information. (Doc. No. 44.) 6 Rimon seeks to withdraw because “Defendants have refused to pay a large amount 7 of money to Rimon for representing Defendants in both this case and in a parallel 8 proceeding pending in the U.S. International Trade Commission,” and has attached a 9 declaration attesting to the same and to the non-prejudicial nature of the motion. (Doc. 10 No. 36 at 4; Doc. No. 36-1, Declaration of Juan Zuniga.) 11 Parties generally may plead and conduct their own cases personally. 28 U.S.C. 12 § 1654. However, “[o]nly natural persons representing their individual interests in propria 13 persona may appear in court without representation by an attorney.” Civ. L.R. 83.3(j). 14 “All other parties, including corporations, partnerships and other legal entities, may appear 15 in court only through an attorney permitted to practice pursuant to Civil Local Rule 83.3.” 16 Id.; see also Rowland v. Cal. Men’s Colony, 506 U.S. 194, 201–02 (1993) (“It has been 17 the law for the better part of two centuries . . . that a corporation may appear in the federal 18 courts only through licensed counsel . . . . [T]hat rule applies equally to all artificial 19 entities.”); United States v. High Country Broadcasting Co., Inc., 3 F.3d 1244, 1245 (9th 20 Cir. 1993) (affirming district court’s entry of default judgment against the corporation 21 when the corporation failed to retain counsel for the duration of the litigation). 22 Here, Rimon seeks to withdraw as counsel of record for Defendant Wu, an 23 individual, and corporate Defendants Ascletis Bioscience, Gannex Pharma, Ascletis 24 Pharmaceuticals, and Ascletis Pharma. Should Rimon be permitted to withdraw as counsel 25 of record for all Defendants, Ascletis Bioscience, Gannex Pharma, Ascletis 26 Pharmaceuticals, and Ascletis Pharma would be without counsel in this action. No counsel 27 has appeared on behalf of Ascletis Bioscience, Gannex Pharma, Ascletis Pharmaceuticals, 28 and Ascletis Pharma. Consequently, permitting this withdrawal would leave Ascletis 1 || Bioscience, Gannex Pharma, Ascletis Pharmaceuticals, and Ascletis Pharma, “artificial” 2 entities, proceeding without counsel in direct contravention to this District’s Civil 3 Local Rules. See Civ. L.R. 83.34); Rowland, 506 U.S. at 201-02. 4 In light of the foregoing, the Court grants, in part, and denies, in part, Rimon’s 5 ||motion to withdraw as counsel without prejudice. (Doc. No. 36.) The Court grants 6 ||Rimon’s motion to withdraw as to Defendant Jinzi Jason Wu. The Clerk of the Court is 7 ||instructed to update Defendant Wu’s contact information as follows: (1) Mailing 8 || Address: 6 Fuchun Road, Shangcheng District, Hanghzhou, Zhejiang, China, 310008; 9 ||and (2) Telephone Number: +86 15088769922. 10 The Court denies without prejudice Rimon’s motion to withdraw as to Defendants 11 || Ascletis Bioscience, Gannex Pharma, Ascletis Pharmaceuticals, and Ascletis Pharma. The 12 ||Court temporarily lifts the stay to allow Ascletis Bioscience, Gannex Pharma, Ascletis 13 ||Pharmaceuticals, and Ascletis Pharma thirty (30) days to obtain substitute counsel and 14 ||have counsel file a notice of appearance. Should such Defendants fail to obtain new 15 |}counsel within the next thirty days, Rimon may file a renewed motion no earlier than 16 || May 9, 2024, to withdraw as counsel of record. If a renewed motion is filed, it should 17 || describe the ongoing efforts to seek new counsel in addition to the ongoing relationship 18 || with Ascletis Bioscience, Gannex Pharma, Ascletis Pharmaceuticals, and Ascletis Pharma. 19 ||In the event that Ascletis Bioscience, Gannex Pharma, Ascletis Pharmaceuticals, and 20 || Ascletis Pharma retain new counsel within the next thirty days, Rimon may immediately 21 ||seek leave to withdraw as counsel. Upon resolution of Rimon’s efforts to withdraw as 22 counsel, the Court will reimpose the stay pending the final decision in ITC Investigation 23 ||No. 337-TA-1352. 24 IT IS SO ORDERED. 25 || DATED: April 8, 2024 | ul |. | | 26 MARILYN #. HUFF, Distri ge 27 UNITED STATES DISTRICT COURT 28